5-HT1B receptor imaging and cognition: a positron emission tomography study in control subjects and Parkinson's disease patients.

Abstract

INTRODUCTION:

The serotonin 5-HT1B receptor subtype is involved in the modulation of serotonin release and is a target of interest for neuroreceptor imaging. Previous studies have shown that the serotonin system is affected in Parkinson's disease (PD). Cognitive function, frequently impaired in PD, has been linked to the serotonin system. The aim of this study was to examine whether 5-HT1B receptor availability in the brain of healthy subjects and PD patients is associated with measures of cognitive function.

METHODS:

Twelve control subjects and ten PD patients with normal mini-mental state examination scores were included in this study. Cognitive function was evaluated by assessment of semantic, episodic, and working memory, as well as fluency and visual attention. Creative ability, a measure of divergent thinking, was examined with the alternative uses of objects task. PET measurements were performed with the 5-HT1B receptor-radioligand [(11) C]AZ10419369 using the HRRT system.

RESULTS:

PD patients showed statistically significant lower measures of semantic and episodic memory, as well as creative ability, compared with control subjects. Statistically significant positive correlations were found in control subjects between creative ability and average 5-HT1B receptor availability in grey matter, and in PD patients between scores of Beck Depression Inventory-II and creative ability.

CONCLUSION:

Though creativity has been conventionally linked to dopamine function, our findings in control subjects suggest a link between 5-HT1B receptor availability and creative ability. In PD patients, creative ability was significantly associated with depressive symptoms but not with 5-HT1B receptor availability. This finding deserves further investigation in future studies.

• Authors: Andrea Varrone, Per Svenningsson, Petter Marklund, Helena Fatouros-Bergman, Anton Forsberg, Christer Halldin, Lars-Göran Nilsson, Lars Farde
• Journal: Synapse (New York, N.Y.) (Synapse) Vol. 69 Issue 7 Pg. 365-74 (Jul 2015) ISSN: 1098-2396 [Electronic] United States
• PMID: 25914348 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2015 Wiley Periodicals, Inc.

Chemical References

• 5-methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-morpholin-4-yl-phenyl)amide
• Benzopyrans
• Morpholines
• Piperazines
• Receptor, Serotonin, 5-HT1B

Topics

• Aged
• Analysis of Variance
• Benzopyrans (pharmacokinetics)
• Brain (diagnostic imaging, drug effects, pathology)
• Cognition Disorders (diagnosis, etiology)
• Female
• Gray Matter (diagnostic imaging)
• Humans
• Magnetic Resonance Imaging
• Male
• Middle Aged
• Morpholines (pharmacokinetics)
• Neuropsychological Tests
• Parkinson Disease (complications, diagnostic imaging, pathology)
• Piperazines (pharmacokinetics)
• Positron-Emission Tomography
• Protein Binding (drug effects)
• Receptor, Serotonin, 5-HT1B (metabolism)
• Severity of Illness Index